Skip to main content
. 2017 Sep 11;8(46):80625–80637. doi: 10.18632/oncotarget.20814

Table 2. ADI-Panels accurately recognize APL patients from AML patients in our multi-centers study.

ADI-Panel MICM Total
APL Non-APL
APL 200 5 205
Non-APL 2 627 629
Total 202 632 834

Note: ADI-Panels, APL diagnostic immunophenotypic panel; MICM, morphology, immunology, cytology, and molecular biology; Data comparisons were performed using McNemar (P = 0.453) and Kappa tests (Kappa = 0.977, P < 0.001).